Melphalan

peptidylglycine alpha-amidating monooxygenase ; Homo sapiens







31 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 25621797 High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. 2015 Apr 1
2 21042310 TBI and melphalan followed by allogeneic hematopoietic SCT in children with advanced hematological malignancies. 2011 Aug 1
3 18999930 Polyethylene glycol conjugates of methotrexate and melphalan: synthesis, radiolabeling and biologic studies. 2008 Oct 1
4 17176891 [Cryotherapy is useful and safe in the prevention of oral mucositis after high-dose melphalan (L-PAM)]. 2006 Nov 1
5 14761920 Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. 2004 Feb 1
6 12189530 Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. 2002 Aug 1
7 11878777 Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. 2001 Nov 1
8 10789721 Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. 2000 May 2
9 11079271 Allograft with unrelated donor accentuates the gastrointestinal toxicity associated with high-dose melphalan and total body irradiation preparative for bone marrow transplantation in children. 2000 Nov 1
10 9548610 Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? 1998 Apr-May 1
11 9670271 Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. 1998 1
12 9679558 L-S,R-buthionine sulfoximine: historical development and clinical issues. 1998 Apr 24 2
13 9951688 Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration. 1998 Dec 1
14 9329556 Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease. 1997 Jul-Aug 1
15 9516845 Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. 1997 Oct 2
16 7622292 Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. 1995 Jul 17 1
17 8004757 In vivo modulation of several anticancer agents by beta-carotene. 1994 1
18 2208589 DNA adenine adducts induced by nitrogen mustards and their role in transcription termination in vitro. 1990 Oct 1
19 2260990 Enhancement of melphalan (L-PAM) toxicity by reductive metabolites of 1-methyl-2-nitroimidazole, a model nitroimidazole chemosensitizing agent. 1990 Dec 15 1
20 3178239 [Reduced cisplatin-uptake by cisplatin-resistant human ovarian cancer cells]. 1988 Oct 1
21 3182309 Melphalan and prednisone plus total bone marrow irradiation as initial treatment for multiple myeloma. 1988 Oct 1
22 3349564 A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma. 1988 1
23 3497748 Differences in sensitivity to melphalan between con A-activated and nonactivated human T-cell subsets. 1987 Oct 1
24 6434498 Chemopotentiation by CB 1954: the importance of postincubations and the possible involvement of poly(ADP-ribosylation). 1984 Sep 1
25 6541216 Modification of alkylating agent cytotoxicity by cisplatin. 1984 Sep 1
26 6546359 Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. 1984 Feb 15 1
27 6882665 Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole. 1983 Aug 1
28 7000345 L-phenylalanine mustard (L-PAM): the first 25 years. 1980 Apr-May 1
29 536450 Application of a simple high-performance liquid chromatographic method for the determination of melphalan in the presence of its hydrolysis products. 1979 Sep 14 1
30 101843 Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. 1978 Dec 7 1
31 1016968 Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU. 1976 Sep 1